Relief Therapeutics Holding SA (OTCMKTS:RLFTF) is a biopharmaceutical company that is involved in bringing on improvements in treatments and therapies for the purpose of benefitting those who may be suffering from rare diseases.
Last week on March 22 the company was in focus after it announced the results from the survey related to preferred urea cycle disorder (UCD) treatment in partnership with ACER Therapeutics Inc. The results from the survey were presented at the 44th Annual Meeting of the Society for Inherited Metabolic Disorders event held on March 19, 2023, in Salt Lake City by Professor Robert Steiner. The survey had been designed to quantify the preferences of healthcare experts when it comes to the treatment of UCD.
The survey revealed that odor and taste were the two most important factors when it came to the writing out of prescriptions with regard to UCD treatment with nitrogen-binding medications. Steiner noted that nitrogen-binding medications could prove to be effective when it came to the treatment of UCD.
However, he went on to add that due to the lack of adherence by patients, diet preferences, and some of the attributes of present-day nitrogen-binding medications, it was necessary to work on alternative options.